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The yeast box-mutant W7 exhibits deficiencies in cytochrome b and in nuclear coded complex III subunits, a phenotype 
observed previously in a patient with mitochondriai myopathy. DNA sequence analysis of mutant W7 revealed a single 
base transition in the cytochrome b gene; the mutated residue Gly 131 is perfectly conserved in all known cytochromes 
b and belongs to the Qo domain. Mutant W7 provides a model system for evaluating the action of therapeutic agents, 
such as vitamin K 3 which restored NADH-oxidase activity in the mutant as well as in the antimycin-inhibited wild type. 
However, with the mutant, a greater quantity of menadione was necessary due to a decrease in other complex activities, 
and a much lower electron-flow fraction passed through cytochrome oxidase. 
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1. INTRODUCTION 
Numerous apocytochrome b mutants defective 
in the ubiquinol-cytochrome c reductase segment 
(complex III) of the mitochondrial respiratory 
chain have been isolated in thcyeast S. cerevisiae 
[1]. The mutant W7, some of the biochemical pro- 
perties of which have been described previously [2], 
is particularly interesting in that it is characterized 
by a low cytochrome b level, a loss of activity in the 
b-c1 segment of the respiratory chain and a 
decrease inother complex III subunits coded for by 
the nuclear genome: core protein I, non-heme Fe-S 
and subunit VI. A similar phenotype has been 
described for the first time in a patient with 
mitochondrial myopathy [3]; the question as to 
whether the primary site of the mutation in this pa- 
tient might be mitochondrial or nuclear has been 
discussed previously [4]. 
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This analogy suggests the possibility of using the 
yeast mutant to test he effects of products liable to 
bypass this genetic defect. The complex III- 
deficient patient has been favorably treated with 
vitamins K3 and C and the rationale for this drug 
therapy was based on known in vitro results with 
antimycin-inhibited yeast [5]. 
We report here the DNA sequence anaIysis of 
mutant W7 and data on the respiratory activity 
restoration i duced by vitamin K3, in antimycin- 
inhibited wild type strain and mutant W7. 
2. MATERIALS AND METHODS 
2.1. Strains 
The diploid wild-type strain PS409 was derived from the 
haploid wild strain of S. cerevisiae 777-3A crossed with the rho ° 
IL126-1C/52; in a similar manner, the isogenic strain PS429 was 
derived from the original cob-box mutant of 777.3A, named 
W7, crossed with the same rho ° [6]. Isonuclear genotype: - /a ,  
op /+,  ade./+, +/ura. 
Cultures, preparation ofmitochondria, spectral nalysis, pro- 
tein, succinate dehydrogenase activity, cytochrome-c oxidase 
and CoQ2H2-cytochrome c reductase activities have been 
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described previously [2,7]. Complex I activities were determined 
spectrophotometrically s in [8]. 
2.2. Sequence analysis 
Mitochondrial RNA isolation and RNA sequencing were per- 
formed as in [9]. Three primers ynthesized by Dr Javer Perea 
(Centre de G6n6tique Mol6culaire, Gif-sur-Yvette) were used 
for the sequencing of the first exon of the cytochrome b gene. 
The position of the primers is given on the basis of their first and 
last bp numbers on the cytochrome b split gene" PI, 109-128; 
P2, 270-298; P3, 2636-2655. 
3. RESULTS AND DISCUSSION 
The respiratory deficient W7 mutant has been 
previously localized at the end (interval 7) of the 
first exon (B1) of the split mitochondrial COB- 
BOX gene coding for apocytochrome b [10]. The 
nucleotidic sequence of the mutated exon was 
analysed here by reverse transcription of the 
cytochrome b mRNA from crude mitochondrial 
RNA preparations as described in section 2. The 
only base change affecting the wild-type sequence 
was a G to A transition ear the end of exon B1, 
leading to the replacement of Gly 131 by serine 
(GGT~AGT). In view of the perfect agreement 
between the genetic mapping and sequencing data, 
it can be concluded that this alteration is in fact 
responsible for the respiratory deficient phenotype 
of mutant W7. 
Gly 131 is perfectly conserved in all the 
cytochromes b, including mammalian and yeast, 
which have been sequenced sofar [11]. This residue 
might be located in the eight transmembrane-helix 
cytochrome b folding model, proposed recently on 
the basis of different calculations [12-14], near the 
presumed electropositive side of the membrane at 
the NH2 terminal of the membrane spanning seg- 
ment number 3 which connects the two heme- 
binding helices, numbers 2 and 4 (fig. 1). The W7 
mutation affects one of the two cytochrome b 
regions (extending from residues 129 to 147 and 
256 to 275) which were found to confer upon 
amino acid replacement an increased resistance to 
inhibitors acting at the Qo site of the bCl complex 
(mucidin, myxothiazol and stigmatellin) [15]. 
The non-respiratory growing W7 mutant has 
been shown previously to be strongly affected in 
the assembly of the bcl complex, as indicated by 
the loss of ability to bind the high-affinity inhibitor 
antimycin [16] and by the drastic reduction in 
several of the enzyme polypeptide subunits it con- 
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Fig. 1. Cytochrome b folding model in the mitochondrial inner 
membrane. This model represents the height transmembrane 
helices model recently proposed by Brasseur [9,14]. Subscript 
numbers, amino acid positions: mutation W7 is noted in posi- 
tion 131. ~ ~ Position of the corresponding exons limits of 
the split cytochrome b gene. 
tains; the spectral cytochrome b content of mutant 
W7 amounted to only 1507o f that of the wild type 
while those of cytochromes c and aa3 were 65 and 
37070, respectively [2]. Activity measurements a  the 
mitochondrial level revealed the nearly complete 
absence of QHz-cytochrome c reductase activity; 
succinate-Q, NADH-Q and cytochrome c oxidase 
activities were substantially reduced by about 83, 
38 and 64070, respectively, vsthe wild type (see table 
1). As a result of the loss of activity in the bCl seg- 
ment of the electron-transfer chain, the respiratory 
measurements showed no succinate oxidase activi- 
ty, and a low NADH oxidase activity which was of 
the same order as the antimycin-inhibited wild-type 
activity (6°70, table 2). 
The phenotype of mutant W7 shows great 
similarities with that of a patient with a deficit in 
complex III of skeletal muscle mitochondria s 
reported by Darley-Usmar et al. [3]. This patient's 
mitochondria exhibited, like mutant W7 mitochon- 
dria, a low reducible level of cytochrome b, a defi- 
ciency in several polypeptides of complex III and a 
severe decrease in ubiquinol-cytochrome c r duc- 
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Table 1 
Comparative activities in the four different segments of the respiratory chain of the wild-type strain and box-mutant W7 
mitochondria 
Mutation Succinate NADH-CoQ2 CoQ2H2- " Cytochrome c 
(strain) dehydrogenase activity cytochrome c oxidase 
activity activity activity 
box + (PS409) 100 100 100 100 
W7 (PS429) 17 62 2 36 
Activities are expressed as a percentage of box + 
tase activity. The possibility of improving oxidative 
phosphorylation has been investigated in this pa- 
tient using therapeutic agents which bypass the 
cytochrome-deficient site. Therapy with mena- 
dione and ascorbate was found to improve 
phosphorylation in the patient, and concomitantly 
to somewhat improve the functional activity [5]. 
Owing to its similarities with this case of 
mitochondrial myopathy due to complex III defi- 
ciencies, the yeast W7 mutant constitutes a model 
system for evaluating the mode of action and the 
efficiency of therapeutic agents. 
The action of vitamin K3 was studied in the defi- 
cient mutant and antimycin inhibited wild-type 
strain. In both strains, with NADH as substrate, 
the respiratory activity accelerated considerably 
after the addition of vitamin K3 (fig.2) and this 
recovery of NADH oxidase activity induced by 
vitamin K3 was correlated in the low-temperature 
spectra with the reduction of cytochromes c and cl 
(not shown). These results uggest that menadione 
may establish a bridge between NADH and 
cytochromes c and Cl so as to bypass cytochrome b,
which is non-functional either because of the 
presence of antimycin or because of the modifica- 
tion induced by the mutation. 
The action of vitamin K3 on the respiratory 
defective mutant and its wild type strain was 
studied at three different levels as shown in table 2: 
(i) NADH induced a reduction in vitamin K3 
through NADH dehydrogenase (which is not in- 
hibited by antimycin); stoichiometric quantitites of 
NADH and vitamin K3 were necessary to ensure 
maximum activity. 
(ii) The NADH cytochrome c activity was very 
low in the mutant; in the wild-type strain inhibited 
by antimycin, only a small quantity of vitamin K3 
was needed to restore the basal activity. A signifi- 
cant activity level was also recovered by mutant W7 
under these conditions (K3 < < NADH). 
(iii) The same was observed with NADH oxidase 
activity. This respiratory activity was studied in 
terms of mitochondrial concentration at two dif- 
ferent values of vitamin K3 (fig.3) and a hyperbolic 
relationship was observed; consequently, the 
recovery of NADH oxidase activity by vitamin K3 
in the mutant and the antimycin-inhibited wild- 
type strain was found to depend on the concentra- 
tion of vitamin K3 per mass of mitochondrial pro- 
tein (fig.4). However, the maximum specific 
NADH-K3 activity (described in [1]) was found to 
be independent of the mitochondrial concentra- 
Table 2 
Action of vitamin K3, observed at three different levels of the respiratory chain, in the wild-type and the missense xonic cytochrome 
b mutant W7 
Mutation NADHa-K3 b NADHa-cytochrome c activity NADHd-oxidase activity 
(strain) activity 
+ Antimycin + K3 c + Antimycin + K3 
box + (PS409) 224 286 50 230 95 6 232 
W7 (PS429) 123 27 170 6 126 
a NADH = 125 v2Vl; b K3 = 120/~M; c K3 = 10/JAM; d NADH =2.5 mM 
Activity assays of NADH-K3 reductase and NADH-cytochrome c reductase were performed in the presence of 2 mM KCN. Activities 
in nmoles, rain - ~' mg - 1. Antimycin, 1 /,M; mitochondria, 0.03 mg of box + and 0.036 mg of W7 in the two first activities; 0.35 rag 
of box + and 0.5 mg of W7 in NADH-oxidase activity. 
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Fig. 2. Action of vitamin K3 on NADH oxidase activity of 
mitochondria solated from the wild-type strain and from the 
missense box mutant W7. Subscripts, respiration rates (in 
nmol.min-I .mg - ~ protein). NADH, 2.5 mM; antimycin, 0.5 
~M; KeN, 2 mM; SHAM, mM; mitochondria, 0.35 mg/ml. 
Box + , 0.52 mg/ml W7; vitamin K3, 20 #M with Box + , 50/zM 
with W7. 
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Fig. 3. Relationship between restored NADH activity and 
mitochondrial content in box mutant W7, for two different 
vitamin K3 concentrations. (A)NADH restored activity in terms 
of mitochondrial-protein co centration. (B)NADH restored ac- 
tivity in terms of inverse of mitochondriai-protein co centra- 
tion. NADH, 2.5 mM. 
tion, as expected; moreover, the vitamin K3 con- 
centration ecessary for this pseudo mono-enzyme 
activity to be reached, was about 3000 nmol/mg 
protein, vs about 300 nmol/mg in the case of the 
other two activities (table 2, W7). This suggests 
that vitamin K3 acts in NADH-K3, as a saturating 
substrate, and in the other two activities as an in- 
termediate r dox component. 
Recovery of normal activity occurred in wild- 
type mitochondria with about 90 nmol vitamin 
K3/mg mitochondrial protein, which is identical to 
the level reported by Nosoh et al. [17]. With the 
box mutant, a 2-fold quantity was necessary to 
reach the same basal activity, which was probably 
related to the reduced activities observed in this 
mutant with the NADH-dehydrogenase and 
cytochrome c-oxidase segment (table 1). 
The respiratory experiments were performed at 
pH 6.3 in order to minimize the autooxidation of
vitamin K3 occurring at pH values above 7. It was 
also noted that quinones may stimulate cyanide- 
resistant respiration [ 18] and we have observed that 
this phenomenon i creases with the quantity of 
vitamin K3 added (unpublished). 
The addition of vitamin K3 with NADH as 
substrate restored the electron flow through the 
NADH dehydrogenase segment in both antimycin- 
inhibited wild type and respiratory-deficient box 
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Fig. 4. NADH oxidase activity restored by vitamin K3 in wild- 
type mitochondria (box +) inhibited by antimycin and in the 
missense mutant of cytochrome b gene, W7. The arrow in- 
dicates the usual wild-type NADH oxidase activity. (+, * ) Two 
different sets of experiments for the wild-type strain PS409 (two 
different mitochondriai preparations); (A, • ,  O) different sets  
of experiments for mutant W7; NADH, 2.5 mM; antimycin, 0.5 
#M. 
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mutant mitochondria;  small part of this electron 
flow went directly through the SHAM sensitive ox- 
idase (fig.2) and the remainder joined the 
respiratory chain at the cytochrome c and cl levels. 
A necessary condition for phosphorylation to be 
restored at site III level is the passing of electron 
flow through cytochrome oxidase; this clearly oc- 
curred with the wild type mitochondria, s the 
restored activity was largely inhibited by cyanide 
(fig.2). With mutant W7, no such inhibition by 
cyanide was observed; on the contrary, cyanide ap- 
peared to stimulate the activity restored by vitamin 
K3 (secondary way) (fig.2); in this case, it is dif- 
ficult to estimate what proportion of electron flow 
may pass through cytochrome-oxidase in the 
absence of cyanide: it is therefore doubtful whether 
site III of oxidative phosphorylation is restored 
with this mutant. However, at the cellular level, 
with ethanol as substrate, the inhibition by KCN of 
vitamin K3-restored respiration is nearly complete 
with the wild type strain (96-98°70) and low 
(30-40070) with the mutant. This will be further in- 
vestigated. 
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